|
99871 |
Assessing the efficacy and safety of Unani pharmacopoeial formulations in dermatophytosis (quba) – a randomized controlled trial Enthalten in Drug metabolism and personalized therapy Bd. 38, 2022, Nr. 2: 169-177. 09 S.
|
|
|
99872 |
CYP2C9 gene polymorphisms influence on antihypertensive effectiveness and hypouricemic effect of losartan among patients with arterial hypertension: an observational study Enthalten in Drug metabolism and personalized therapy Bd. 38, 2022, Nr. 2: 163-168. 06 S.
|
|
|
99873 |
Actionable mutations in non-small cell lung cancer in patients at hospital de Especialidades Eugenio Espejo, Ecuador 2017–2020 Enthalten in Drug metabolism and personalized therapy Bd. 38, 2022, Nr. 2: 149-153. 05 S.
|
|
|
99874 |
Effect of CYP2D6*4, CYP2D6*10 polymorphisms on the safety of treatment with timolol maleate in patients with glaucoma Enthalten in Drug metabolism and personalized therapy Bd. 38, 2022, Nr. 2: 143-148. 06 S.
|
|
|
99875 |
AOTrauma Studentenkurs in Freiburg – to train the next Generation Enthalten in OP-Journal Bd. 38, 2022, Nr. 02: 140-141
|
|
|
99876 |
Long-Term Opioid Use Following Surgery for Symptomatic Neuroma Enthalten in Journal of reconstructive microsurgery Bd. 38, 2022, Nr. 02: 137-143
|
|
|
99877 |
AO Trauma Dreiländertagung - Deutschland – Österreich – Schweiz Enthalten in OP-Journal Bd. 38, 2022, Nr. 02: 134-137
|
|
|
99878 |
The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders Enthalten in Drug metabolism and personalized therapy Bd. 38, 2022, Nr. 2: 133-142. 10 S.
|
|
|
99879 |
Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review Enthalten in Visceral medicine Bd. 38, 2022, Nr. 2: 126-132. 7 S.
|
|
|
99880 |
Hyperthermic Intraperitoneal Chemotherapy in the Treatment Armamentarium of Epithelial Ovarian Cancer: Time to End the Dichotomy Enthalten in Visceral medicine Bd. 38, 2022, Nr. 2: 109-119. 11 S.
|
|